PECAM1 and neoplasm: Significant differences in MVD were detected using the endothelial cell marker CD31 in the erlotinib group versus the control group (p = 0.007) and erlotinib combined with bevacizumab group versus the control group (p = 0.004) in the gefitinib-sensitive tumor model (Fig 5A).